Presseaussendungen zu "Novo Nordisk"

202 Aussendungen
vorige Seite Seite 1 von 14 nächste Seite

4D pharma plc beruft unabhängige nicht geschäftsführende Mitglieder der Geschäftsleitung

4D pharma plc (AIM: DDDD), ein führendes Pharmaunternehmen in der Entwicklung lebender Biotherapeutika, hat heute die Ernennung von Ed Baracchini, Ph.D, und Professor Axel Glasmacher, MD, als unabhängige …

08.01.2019 08:11

People With Diabetes May Achieve Improved Glycaemic Control With Tresiba® Versus Glargine U100, Without an Increase in Hypoglycaemia

According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA1c) with Tresiba® (insulin degludec) versus insulin …

02.10.2018 12:01

Ryzodeg® Offers a Simpler Solution With Once-Daily Dosing and Reduced Risk of Nocturnal Hypoglycaemia vs Insulin Glargine U100 Plus Insulin Aspart

When treated with once-daily Ryzodeg®, people with type 2 diabetes achieved similar blood sugar control with half the number of daily injections, significantly lower total daily insulin dose and …

02.10.2018 12:00

Addressing Social and Cultural Drivers of Type 2 Diabetes is Key to Its Treatment and Prevention

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural factors.[1] Researchers …

02.10.2018 12:00

Roche unterschreibt Kooperationsvertrag für erweiterten Zugang zu Therapieinformationen durch die Einbeziehung von Insulinwerten aus konnektiven Pens in ihr offenes Ökosystem

Roche (SIX: RO, ROG; OTCQX: RHHBY) gab heute bekannt, dass ein Entwicklungs- und Kooperationsvertrag mit Novo Nordisk unterzeichnet wurde, einem Unternehmen, das weltweit führend innovative Therapien für …

01.10.2018 14:31
in Chronik

New Phase 2 Data for Somapacitan Demonstrate Its Potential as an Efficacious Once-weekly Treatment for Childhood Growth Hormone Deficiency

Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial …

28.09.2018 08:41

Ozempic® Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline

Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major …

26.08.2018 14:00

Das Shared Services and Outsourcing Network präsentiert die Nordic Business Transformation: Nordic BT 2018 transformiert die Backoffices der Zukunft

Wandel oder Untergang ist die Botschaft des Tages - Wandel wird der bestimmende Faktor für den Erfolg zukünftiger Unternehmen sein.

12.07.2018 05:41

Tresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin

23.06.2018 16:13

Ozempic® Provided Greater Weight Reductions for Adults With a Baseline BMI >=25kg

m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

23.06.2018 16:10

Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the …

23.06.2018 16:07

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda®

People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise.

24.05.2018 08:03

Head-to-Head Trial Shows Refixia® Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia® (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein).

21.05.2018 11:47
vorige Seite nächste Seite